PhD – Novo
Jeroen Bakker is currently a Principal at Novo Holdings and is part of the Novo Seeds team focusing on company creation and early-stage financings. Previously, Jeroen worked at M Ventures, the corporate investment group of Merck KGaA, focusing on early-stage investments in US, EU and Israel. Jeroen worked previously in target discovery at Syntaxin Ltd (acquired by Ipsen) and carried out research at the La Jolla Institute for Allergy and Immunology and University of Iowa. He obtained his BSc from the Technical University Delft, MSc from the Leiden University with a specialization in entrepreneurship and PhD from the University of Amsterdam in the field of immunology. He represents Novo Holdings as a director on the board of Antag Therapeutics, ISD Immunotech, Rappta Therapeutics and is an observer on the board of Inthera Biosciences.